Galena Biopharma Inc. is all but hat in hand, launching a registered direct offering July 8 to raise additional funding as it made public its intention to have a third party review the operational information from a recently halted Phase III trial of its NeuVax to determine what possible factors, other than efficacy, caused the breast cancer vaccine candidate to fail a futility analysis.
Galena Left To Hope Review Of Trial Operations Rescues NeuVax
Cancer vaccine development is a tricky undertaking, but Galena may be grasping at last straws with a third-party review of a recently halted study of NeuVax, hoping to discover operational reasons for cancer vaccine's poor performance.